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Introduzione 
Il CA19.9 è uno dei marcatori tumorali più utilizzati sia nella ricerca che nella pratica 
clinica. La sigla CA19.9 identifica un gruppo eterogeneo di molecole aventi come 
struttura terminale il tetrasaccaride sialil Lewis a (sLea), uno degli antigeni del 
gruppo Lewis con catena saccaridica cosiddetta di tipo 1. Questo gruppo comprende 
anche il Lewis a (Lea), il Lewis b (Leb) e il disialil Lewis a che sono comunemente 
considerati dei prodotti fisiologici dell’epitelio del tratto gastrointestinale. Viceversa, 
il CA19.9 viene annoverato tra i prodotti delle cellule tumorali. Questa convinzione è 
dovuta principalmente a studi immunoistochimici che hanno evidenziato intense 
colorazioni dei tessuti tumorali utilizzando l’anticorpo anti-CA19.9 (che riconosce 
specificamente il sLea).  
La glicosiltrasferasi B3GALT5 è uno degli enzimi necessari alla sintesi degli antigeni 
Lewis con catena di tipo 1. La sua trascrizione genica è sotto il controllo di vari 
promotori che presiedono alla sintesi di trascritti differenti nella regione 5’UTR ma 
identici nella sequenza codificante. Paradossalmente per la sintesi di un marcatore 
tumorale, questi trascritti sono silenziati nel tumore del colon. Inoltre il CA19.9 è 
scarsamente riconoscibile nei lisati di tumore del colon analizzati mediante dot-blot 
e studi condotti nel nostro laboratorio hanno dimostrato che l’anticorpo specifico per 
il CA19.9 reagisce per immunoistochimica colorando anche i tessuti murini che, 
però, mancano costitutivamente della fucosiltransferasi necessaria alla sintesi 
dell’epitopo e che quindi sono sicuramente privi dell’antigene.  
 
SCOPO 
Data la rilevanza che ha assunto il CA19.9 come marcatore tumorale, il nostro studio 
mira a rivisitare da un punto di vista istologico, biochimico e molecolare l’espressione 
in vivo degli antigeni Lewis al fine di appurare la loro effettiva importanza ed utilità 
nel cancro gastrointestinale.  
 
MATERIALI E METODI 
I livelli di espressione e la sintesi degli antigeni Lewis con catena di tipo 1 sono stati 
valutati nel colon e nel pancreas mediante immunofluorescenza, immunoistochimica 
e dot-blot; i trascritti delle glicosiltrasferasi sono stati quantificati mediante real time 
PCR; gli studi epigenetici sono stati realizzati mediante sequenziamento con bisolfito 
e saggi di immunoprecipitazione della cromatina. 
 
RISULTATI 
Il CA19.9 si è dimostrato poco visibile nella mucosa normale di colon e ancor meno 
nel tumore, viceversa era ben individuabile (così come il Leb) nei dotti pancreatici, 
sia nella parte sana che nella parte tumorale dei campioni analizzati. I trascritti della 
B3GALT5 sono risultati regolati negativamente nel tumore del colon, a differenza dal 
tumore del pancreas dove si è invece mantenuta la loro espressione. Allo stesso 
modo l’ST3GAL3 è risultata espressa nel pancreas in modo indipendente dalla 
trasformazione tumorale mentre i suoi livelli di espressione nel colon sono risultati 
comunque bassi. Nel tumore del pancreas il livello di metilazione delle isole di CpG 
fiancheggianti il promotore nativo della B3GALT5 è risultato decisamente inferiore 
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rispetto a quello individuato nel tumore del colon. Inoltre abbiamo individuato una 
regione distante circa 1 Kb dal promotore retrovirale della B3GALT5 costituita da 
una significativa densità di dinucleotidi CpG (stretch di CG) il cui tipo di metilazione 
era potenzialmente associato alla trascrizione. Questa ipotesi è stata corroborata 
dai risultati ottenuti mediante immunoprecipitazione della cromatina. Abbiamo infatti 
trovato un arricchimento degli istoni analizzati di tipo sovrapponibile a quello ottenuto 
con la regione di legame del fattore di trascrizione.  
 
CONCLUSIONI 
I nostri risultati dimostrano che il CA19.9 è un prodotto fisiologico la cui sintesi è 
fortemente regolata dalla B3GALT5 e dall’ST3GAL3. Nel pancreas sembra 
assumere le caratteristiche di marcatore tumorale in seguito ad ostruzione dei dotti 
o ad una inversione della polarità delle cellule duttali. Ciò comporta il riassorbimento 
dell’antigene nei vasi e un conseguente aumento dei suoi livelli sierici. Lo stesso 
meccanismo potrebbe anche aumentare i livelli serici degli altri antigeni Lewis, che 
potrebbero essere utilmente impiegati clinicamente per monitorare i pazienti di 
cancro pancreatico CA19.9 negativi.   
 
 
 
ABSTRACT  
 
Background  
CA19.9 is one of the more diffusely used tumor markers in both research and clinical 
practice. It consists of a heterogeneous group of molecules that share the terminal 
sialyl Lewis a (sLea) structure, one of the so-called type 1 carbohydrate-chain Lewis 
antigens, which also include Lewis a (Lea), Lewis b (Leb) and disialyl-Lewis a. Lea, 
Leb and disialyl-Lea have been considered products of the epithelia of the normal 
gastrointestinal tract, while CA19.9 has been assumed as an abundant product of 
cancer cells, due to the reactivity found by immunohistochemical staining of cancer 
tissues with the anti CA19.9 antibody (recognising sLea).  
B3GALT5 is one of the glycosyltransferase enzymes required for synthesizing such 
antigens, whose gene transcription is under the control of multiple promoters able to 
drive synthesis of transcripts with different 5’ UTRs but identical coding sequence. 
Paradoxically for the biosynthesis of a tumor marker, all transcripts appear silenced 
in colon cancer. Moreover, CA19.9 was scarcely detectable by dot-blot staining of 
colon cancer lysates and we recently found a false reactivity with anti-CA19.9 
antibody of mouse tissues stained by immunohistochemistry, since sLea is not 
synthesized in the rodents due to the lack of any 1,4 fucosyltransferase activity. 
 
Aim  
Regarding the current concept of CA19.9 as a tumor marker, our study aims at 
revisiting the histological, biochemical and molecular aspects of Lewis antigen 
expression in vivo and to assess their actual relevance in different cancers.  
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Methods  
Expression and biosynthesis of type 1 chain Lewis antigens in the colon and the 
pancreas were studied by immunodetection in tissue sections and lysates, 
quantification of glycosyltransferase transcripts, bisulfite sequencing, and chromatin 
immunoprecipitation assays.  
 
Results  
CA19.9 was poorly detectable in normal colon mucosa and almost undetectable in 
colon cancer, while it was easily detected in the pancreatic ducts, together with Lewis 
b antigen, under both normal and cancer conditions. B3GALT5 transcripts were 
down-regulated in colon cancer, while they remained expressed in pancreatic 
cancer. Even ST3GAL3 transcript appeared well expressed in the pancreas but 
poorly in the colon, irrespective of normal or cancer conditions. CpG islands flanking 
B3GALT5 native promoter presented an extremely low degree of methylation in 
pancreatic cancer with respect to colon cancer. In a DNA region about 1 kb away 
from the B3GALT5 retroviral promoter, a stretch of CG dinucleotides presented a 
methylation pattern potentially associated with transcription. Such a DNA region and 
the transcription factor-binding site provided overlapping results by chromatin 
immunoprecipitation assays, corroborating the hypothesis.  
 
Conclusions  
Our results suggest that CA19.9 is a physiological product whose synthesis strongly 
depends on the tissue specific and epigenetically regulated expression of B3GALT5 
and ST3GAL3. It acquires tumor marker properties in the pancreas due to duct 
obstruction and/or to inverted polarity of transformed ductal cells, which in turn give 
rise to reabsorption into vessels and elevation of circulating levels. The data also 
suggest that other Lewis antigens may share the same properties.  
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1.1 Gastrointestinal tumors: statistical data and most important 
aspects 
1.1.1 Brief statistical report 
Cancer represents a severe health challenge worldwide that is expected to 
increase due to the growth and aging of the population, as well as to the 
adoption of behaviors and lifestyles known to favor cancer. According to The 
World Health Organization, in 2012 8.2 million people died for cancer and 
approximately 14 million new cases appeared [1]. In addition, over the next 
two decades it is expected that the annual new cancer cases will rise to 22 
million [1].  
Gastrointestinal cancer is a collective term for cancers affecting the digestive 
system. This includes the cancers of the esophagus, gallbladder, bile ducts, 
liver, pancreas, stomach, small intestine, colon, rectum, and anus.  
Despite advances over the last decade in understanding the etiology of these 
malignancies, gastrointestinal cancers collectively remain the most lethal 
malignancies worldwide [2].  
In this context, colorectal and prostate cancers are the most common after 
lung and breast cancer (in women), with1.4 million and 1.1 million new cases 
diagnosed in 2012 [3], respectively (Figure 1). 
Although the diagnostic and therapeutic approaches have improved in recent 
years, they are not yet sufficient to overcome the emerging problem of 
cancer, which requires new and more effective tools.  
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FIGURE 1: Estimated most common cancer cases worldwide. 
Colorectal cancer: 10% of all cancers diagnosed (1.4 million people). 
Prostate cancer: 8% of all cancers diagnosed (1.1 million people). 
Source GLOBOCAN 2012. 
 
 
1.1.2 Colorectal cancer 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the 
world accounting for 10% of the estimated 14.1 million new cancer cases 
registered in 2012. Moreover, it is the third leading cause of cancer-related 
death in women and the fourth in men, with 693,600 deaths occurring 
worldwide in 2012 [3]. 
CRC is a multifactorial disease process, with etiology encompassing genetic 
factors. The vast majority of CRC cases have been linked to environmental 
causes, while approximately 30% of all CRC cases are an inherited form of 
the disease [4]. 
This tumor develops as the result of the progressive accumulation of genetic 
and epigenetic alterations that lead to the transformation of normal colonic 
epithelium into colon adenocarcinoma. 
Two main genetic mechanisms play a prominent role in the occurrence of 
CRCs: 
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 Chromosomal instability (CIN) pathway, characterized by 
accumulation of mutations in tumor suppressor genes and oncogenes, as 
well as by other epigenetic changes such as hyper- or hypomethylation of 
DNA, which drive the cells to become malignant.  
The concept of the multi-step ‘adenoma–carcinoma’ sequence involves 
the inactivation of APC (a tumor suppressor gene) and the subsequent 
stepwise mutation of several other genes such as KRAS and TP53 [5]. 
Germline APC mutations initiate the neoplastic process in patients with 
familial adenomatous polyposis (FAP) and endow all colonic crypt stem 
cells with a high risk of clonal proliferation [5]. Moreover, approximately 
70% of colorectal carcinoma develops sporadically through the loss of 
heterozygosity (LOH) following inactivation of the APC gene [6] (Figure 
2). 
 
 Suppressor pathway, also known as MSI (Microsatellite Instability), 
in which inactivation of the mismatch repair genes (MMR) leads to the 
accumulation of mutations, such as insertions or deletions, in 
microsatellites (repetitive DNA sequences). Microsatellite mutations may 
lead to genomic instability, which in turn may accelerate further 
accumulation of mutations in other cancer genes during tumorigenesis [7]. 
Microsatellite instability is involved in the genesis of about 15% of sporadic 
CRCs and most of HNPCC (hereditary nonpolyposis colorectal cancer) 
[6, 8], and may results from mutations affecting different mismatch repair 
genes [9]. In particular, heterozygous germ-line mutations in genes MSH2 
and MLH1 are responsible for most HNPCC families, while MSH6 and 
PMS2 are less frequently involved [9, 10] (see Figure 3 for details).  
 
5 
 
 
FIGURE 2: Conceptual model for colon cancer carcinogenesis. From normal epithelium 
to carcinoma with two molecular pathways of genomic instability: microsatellite instability 
(MSI) and chromosomal instability (CIN) [11]. 
 
 
In addition to genetic mutations, aberrant methylation of DNA is frequently 
found in CRCs. It includes global hypomethylation of promoters, which leads 
to overexpression of oncogenes and can results in chromosomal instability 
[12], and  MLH1 silencing due to hypermethylation of its promoter [13] (Figure 
2). 
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FIGURE 3: A) The DNA mismatch repair (MMR) mechanism. MMR proteins lead to excision of 
replicated DNA containing an error and to restore DNA integrity. An aberration in one of the MMR 
genes prevents accurate repair of base mismatches produced during DNA replication, resulting in 
production of a DNA chain of altered length. This phenomenon is called microsatellite instability 
(MSI) and can lead to an increased frequency of errors in target genes involved in carcinogenesis, 
resulting in cancerization of the cell. B) HNPCC mutations.  Mutations in MLH1 and MSH2 account 
for about 90% of all HNPCC mutations (source: Affiliated Pathologists Medical Group, APMG). 
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A number of different staging criteria have been used to estimate the depth 
of cancer penetration in the colon as well as the extent of extra-colonic 
involvement. Currently, a commonly used staging method for colon cancer is 
based on the TNM (tumor/node/metastases) system as delineated by the 
American Joint Committee on Cancer (AJCC), now in its 7th edition [14]. 
According to this system, early stage colon cancer can be defined as a lesion 
that has been completely resected with no subsequent evidence of 
involvement of adjacent organs, lymph nodes or distant sites. While these 
cases are usually curable, in the advanced stage of the disease the 
prognosis becomes poor, due to metastatic involvement of lymph nodes or 
other organs [14]. 
Although current clinical practice in colorectal cancer screening (fecal occult 
blood test and colonoscopy) has contributed to a substantial rise in survival 
over the last two decades, the 5-year disease-specific overall survival rate is 
still < 60% [9]. Moreover, 70% of newly discovered CRC are detected at an 
advanced stage, presenting poor patient prognosis [15]. Thus, in order to 
eradicate CRC death, early detection is a crucial point, and identification of 
diagnostic markers should be urgently developed.  
Currently, available serum tumor markers are carcinoembryonic antigen 
(CEA) and  carbohydrate antigen CA19.9, but their clinical usefulness is 
controversial for clinical assessments in diagnostic, prognostic, and 
surveillance protocols [15].  
 
1.1.2 Pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplasia 
of the exocrine pancreas [16]. As one of the most aggressive human 
malignancies, it presents an exceptionally rapid progression [9-11].  
Early stage pancreatic cancer is generally clinically silent. First symptoms of 
pancreatic cancer become apparent only after tumor invasion of surrounding 
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tissues or even metastasis to distant organs, leading to a later diagnosis [17, 
18]. As a result, PDAC patients have an extremely poor prognosis and the 
five-year survival rate is only 7% [19].  
Although PDAC is the fourth leading cause of cancer death in Europe and 
the United States, it is not found among the most common cancers; new 
cases of PDAC represent, in fact, only 3% of all cancers diagnosed [3, 19]. 
At the same time, this tumor has been projected to become the second 
leading cause of cancer-related deaths by 2030 [20].  
PDAC is a heterogeneous disease at the molecular, pathological, and clinical 
levels. According to the American Cancer Society, 10% of PDAC may be 
caused by an inherited DNA alteration, meaning a genetic predisposition to 
cancer due to family lineage. There are different identified PDAC precursor 
lesions that affect the pancreatic ducts [21, 22] : 
 intraductal papillary mucinous neoplasm (IPMN); 
  mucinous cystic neoplasm (MCN); 
 pancreatic intraepithelial neoplasia (PanIN), which is the most common 
PDAC precursor lesion [5, 20]. These non-invasive precursor lesions 
reflect different grades of dysplasia in the epithelium of the pancreatic 
ducts, while the high-grade PanIN (PanIN-3) may be converted into 
invasive pancreatic ductal adenocarcinoma [23] (Figure 4).  
Some of the major molecular alterations involved in PDAC carcinogenesis 
are known. Pancreatic cancer, like other cancers such as breast and lung 
cancer, results from the accumulation of gene mutations.  
They include the activation of KRAS, HER2/neu, BRCA2, AKT2, and BRAF 
oncogenes, and the inactivation of p16/CDKN2A, TP53, and SMAD4/DPC4 
tumor suppressor genes [24, 25].  
 KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) oncogene mutation 
occurs in 95% of patients with PDAC [26]. Mutations of KRAS, impair 
intrinsic GTPase activity of the KRAS protein. This leads to activation of 
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KRAS downstream pathway that drives tumor progression. Mutations in 
KRAS are typically present in the PanIN lesions, being the earliest genetic 
alteration that promotes formation of PDAC and leading to cell proliferation, 
differentiation or survival. 
 CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A), also known as p16, is a 
tumor suppressor gene that inhibits cell cycle progression through the G1-
S checkpoint. CDKN2A is inactivated in 90% of patients with PDAC and is 
found in PanIN-2 precursor lesions. Loss of function occurs by either 
homozygous deletion, intragenic mutation or epigenetic silencing by 
promoter methylation [27]. 
 The TP53 protein is a fundamental regulator of genome integrity and plays 
an important role in regulation of cell cycle, such as G1-S checkpoint, G2-
M arrest and induction of apoptosis. Loss of TP53 has been found in 
approximately 50%–75% of patients with PDAC [28], whereas gene 
mutations are found in PanIN-3 lesions. Morton and coworkers have shown 
that p53 loss or mutation permits growth of KRAS-mutated cells and 
promotes progression of premalignant lesions to PDAC through failed 
growth arrest and senescence [29].  
 SMAD4 (Mothers Against Decapentaplegic Homolog 4) deficiency can 
inhibit TGF-β-induced cell cycle arrest and migration, contributing to tumor 
formation. SMAD4 inactivation are late events and can be detected in 
PanIN-3 and intraductal papillary mucinous neoplasm and are mainly 
evident in carcinomas [27].  
 HER2/neu is overexpressed in approximately 70% of infiltrating ductal 
carcinomas of the pancreas [30]. 
  Inactivation of BRCA2 is a rare event in pancreatic carcinogenesis, 
occurring in 7-10% of PDACs [31] only.  
 The mutations in BRAF  [32] and AKT2 [33, 34] genes occur in 5% and 10-
20% of PDAC tumors, respectively.  
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FIGURE 4: Model for the histological and genetic progression of pancreatic cancer:  
from normal cells through a series of histologically defined precursor lesions (PanIN) to 
invasive pancreatic cancer (left to right) [35]. 
 
 
PDAC patients are classified into different groups: resectable, borderline 
resectable, locally advanced, and metastatic disease. Unfortunately, the 
majority of PDAC patients (80-85%), are diagnosed with advanced 
unresectable disease [5] and only 15–20% of PDAC cases can be expected 
to be resectable [35]. 
Surgery is the only potentially curative treatment, but due to the frequently 
late diagnosis of PDAC (approximately 40% of patients show distant 
metastases and between 30–40% have locally advanced neoplasms at the 
time of diagnosis), surgery is not always feasible. Under these 
circumstances, chemotherapy and radiotherapy are the most suitable 
options. Despite advances in surgical approaches, post-operative survival 
rates have not improved significantly over the past decades.  
Unfortunately, not a single tumor marker has been approved for early PDAC 
diagnosis. However, CA19.9 and CEA are widely used in clinical settings, to 
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distinguish PDAC from other cancers, monitor recurrences, and evaluate 
responses to therapy.  
1.1.4 Tumor markers 
The term “tumor markers” is commonly used to define biological 
molecules that indicate the presence of cancer or provide information 
about progression or response to therapy [36].  
There are a great variety of markers, such as proteins, nucleic acids, 
antibodies, or peptides [37]; alternatively, a biomarker can also be 
understood as a collection of alterations involving gene expression, 
proteomic, and metabolomic signatures. These molecules can be found in 
the circulatory system, in excretions or in secretions. 
The molecular alterations found in patients with malignancies can be due to 
several factors, including germ-line or somatic mutations, as well as 
transcriptional and posttranslational modifications [37]. 
The main characteristics for an ideal tumor marker should be the following:   
 high sensitivity (the proportion of cancer patients identified correctly) and 
specificity (the proportion of non-cancer  patients identified correctly).  
 High positive and negative predictive value [36]. In particular, the positive 
predictive value is the probability that subjects with a positive test truly 
have the disease, while the negative predictive value is the probability that 
subjects with a negative test truly do not have the disease. 
 Accuracy in differentiating between healthy individuals and tumor patients 
and between neoplastic and non-neoplastic diseases [38].  
 Suitable for early detection of the disease, prediction of response or 
resistance to specific therapies, and for the follow-up of the patients after 
primary therapy [39].  
Unfortunately, a tumor marker that possesses all these characteristics does 
not exist [36]. Despite this, in the management of patients with cancer a 
number of markers are still indispensable. 
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Over the years, many ways to classify biomarkers have been used. 
According to their origin, they can be classified into two different categories:  
 tumor-derived markers, which are produced by neoplastic cells; 
 tumor-associated antigens, which include substances produced by 
normal tissue in response to the presence of the neoplastic cells.  
Moreover, cancer biomarker can be distinguished on the basis of their 
different clinical use and the main categories are listed below.  
A diagnostic tumor marker can be used in the detection of malignant 
disease in a patient. If the marker is used for screening purposes, it should 
exhibit high levels of diagnostic sensitivity more than specificity, and to be of 
clinical value. A prognostic marker is commonly used to assess the risk of 
disease recurrence and/or cancer-related death for a patient, following the 
initial surgical removal of the cancer without administration of adjuvant 
therapy, and independently of the effects of future treatments. Predictive 
tumor markers are associated with either response or resistance to a 
specific therapy [40, 41]. Finally, monitoring markers are useful for the 
detection of recurrence or remission and are used during the follow-up of 
patients undergoing therapy [41]. 
A change in the tumor marker value during treatment is expected to reflect a 
change in the disease status [41]. Moreover, the early detection of 
recurrent/metastatic disease, immediately followed by the treatment, should 
enhance the chances of cure and hence of survival. However, these 
assumptions are not supported by current evidences and the marker values 
are not so obvious [36].  
A typical example of monitoring marker is the CA19.9 [41] (see next 
paragraph). 
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1.1.5 CA19.9 as a tumor marker 
CA19.9 is one of the more diffusely used tumor markers in both research and 
clinical practice. This antigen was first defined by a monoclonal antibody (NS-
1116-19-9) obtained upon immunization with a membrane extract prepared 
form the colon carcinoma cell line SW-1116 [42]. It was later characterized 
as a heterogeneous group of glycoconjugates, including N- and O- linked 
glycoproteins, some of mucin type, and glycosphingolipds. They all share the 
terminal NeuAcα2,3Galβ1,3[Fucα1,4]GlcNAc sequence, named sialyl-Lewis 
a tetrasaccharide (sLea), representing the actual epitope [43, 44] (Figure 5). 
 
 
NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAc- 
 
 
 
 
 
 
 
 
 
FIGURE 5: Chemical structure of sialyl Lewis a 
(Extracted and modified from [45]). 
 
 
CA19.9 is synthesized by biliary and pancreatic ducts as well as by gastric, 
colonic, endometrial, and salivary normal epithelial cells [46]. 
The antigen is detectable in the serum and other biological fluids or extracts 
through RIA or ELISA procedures, and elevated serum values are associated 
with various pathological conditions. 
Currently, CA19.9 has a primary role in the management of gastrointestinal 
cancers in order to monitor the response to therapy and predict recurrence 
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of carcinoma during follow-up [46], although its reliability is accepted for 
pancreatic cancers only [47]. Particularly, increased serum levels of this 
marker above the standard cut-off of 37 U/ml are associated with tumors of 
the pancreatobiliary system [48], and considered a sign of recurrence or 
metastatic lesions [49]. 
Overall, the assay (albeit not exclusive) has a reported sensitivity of 80% and 
speciﬁcity of 90% for the diagnosis of pancreatic carcinoma [48].  
Despite its widespread use in clinical practice, the efficacy of CA19.9 as a 
tumor marker remain controversial and several limitations undermine is utility 
as a tumor marker for pancreatic cancer. 
First, the diagnostic utility of CA19.9 is limited due to a low or modest 
sensitivity (79-81%) in symptomatic patients and a low positive predictive 
value (0.9%). Second, CA19.9 serum levels fail to identify early/small tumors 
or precancerous lesions even in individuals at high risk of developing 
pancreatic cancer (such as hereditary pancreatitis, family history of 
pancreatic cancer, or Peutz-Jeghers syndrome) (10-15% of cases). Third, 
CA19.9 serum levels alone cannot differentiate between benign or precursor 
lesions and malignant pancreatic conditions, and are not predictive of tumor 
location or differentiation. 
It also important to remember that the use of CA19.9 is limited by false 
positivity (10-30%) [50] due to patients suffering benign diseases and  false 
negativity [51, 52]. 
In particular, regarding the first issue, elevated CA19.9 levels can be 
observed in patients suffering non-malignant diseases [52, 53], such as 
chronic pancreatitis [54], liver cirrhosis, cholangitis [55], obstructive jaundice 
[46], and lung diseases [52] (Table 1). 
 
 
 
15 
 
Organ/system Pathologic condition CA 19-9 range (U/mL) 
Pancreatic diseases 
Acute pancreatitis 
Chronic pancreatitis 
Pancreatic abscess 
Pseudo-pancreatic cyst 
3-22 
 
 
Hepato-biliary diseases 
 
Cholangio-carcinoma 
Cholangitis 
Choledocholithiasis 
Cholelithiasis 
Cirrhosis of liver 
Hepatitis 
Hepatocellular carcinoma 
Liver cyst 
Liver abscess 
Polycystic liver disease 
 
50-99000 
 
 
GI malignancies 
Colorectal cancer 
Esophageal cancer 
Gastric cancer 
 
37-100 
 
 
Miscellaneous 
Bronchitis 
Congestive heart failure 
Cystic fibrosis 
Diverticulitis 
Hashimoto's thyroiditis 
Lung cancer 
Ovarian cyst 
Pleural effusion 
Renal cyst 
Rheumatoid arthritis 
 
112-1338 
 
TABLE 1: False positive elevations of CA19.9 serum levels detected in various 
pathological conditions (table extracted and modified from [50]). U/mL: unit/milliliter. GI: 
gastrointestinal. 
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The second issue concerns the impossibility to detect CA19.9 in the subjects 
with the Lewis negative phenotype (representing about 5-10% of the 
population [56]) that lack the 1,4 fucosyltransferase activity required for the 
biosynthesis of type 1 chain Lewis antigens, including sLea (see over for 
details on glycosylation). Therefore, they cannot express sLea, even in 
presence of advanced pancreatic tumor.  
Together, these critical aspects make the effectiveness of CA19.9 doubtful 
and bring limitations in interpreting the clinical course.  
Over the last three decades, there have been many investigations aimed at 
developing a surrogate biomarker, but unfortunately none of these has been 
shown to be superior to CA19.9 in terms of sensitivity and specificity [55]. 
Therefore, improvements to the CA19.9 assay are clearly needed for a better 
management of gastrointestinal cancers. 
The MEDLINE database contains over 2600 articles dealing with CA19.9, 
and their number per year has constantly increased from the 80s to date, 
reaching over 250 in 2015. Moreover, recent epidemiological survey reported 
that the number of serum CA19.9 determinations routinely performed in 
some Western country is enormous, largely exceeding the number expected 
on the basis of the prevalence of the diseases for which it is recommended 
by the scientific literature [57, 58]. In fact, medical associations provided 
rather restrictive recommendations, suggesting that  CA19.9 should be used 
as a tumor marker only for the management of pancreatic cancer, but not for 
the early diagnosis or for other gastrointestinal cancers [55].   
Notwithstanding such a big number of data, the rationale underlying the 
clinical use (or perhaps abuse) of CA19.9 as a tumor marker has never been 
addressed in detail and remains ambiguous. Is the circulating antigen 
produced by the cancer cells but not by their normal counterparts? Is the 
ability to produce CA19.9 common to cancer cells originated from different 
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types of gastrointestinal tissues? Why is CA19.9 a tumor marker while the 
other type 1 chain Lewis antigens are not?  
The work presented in this thesis is aimed at answering these questions, 
supposed to be obvious for a tumor marker, which have never been given 
for CA19.9.  
1.2 Abnormal glycosylation in gastrointestinal cancers 
1.2.1 Glycans and glycoconjugates 
Glycans (N- and O-linked to proteins or linked to sphingolipids) are structural 
components of the cell surface or part of secreted glycoproteins, which 
transmit information from the cells to the environment to control fundamental 
aspects of cell behavior [59], including differentiation, development, 
fertilization, inflammation, and cell–cell recognition [60].  
Glycans can be covalently linked to proteins or lipids in the process called 
glycosylation, thus forming different types of glycoconjugates (Figure 6). 
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FIGURE 6 : Major classes of glycoconjugates and glycans present on the surface or 
inside the eukaryotic cells [61]. A glycoprotein is a glycoconjugate in which a protein carries 
one or more carbohydrate chains (glycans) covalently attached to a polypeptide backbone, 
usually via asparagine (N-linked) or serine/threonine (O-linked). A proteoglycan is a 
glycoconjugate that has one or more glycosaminoglycan (GAG) chains attached to a “core 
protein”. A glycophosphatidylinositol anchor is a glycan bridge between phosphatidylinositol 
and a phosphoethanolamine that is linked to a protein.  A glycosphingolipid (often called a 
glycolipid) consists of a glycan usually attached to a ceramide, which is a lipid composed of a 
long chain base (sphingosine) and a fatty acid.  
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Glycoconjugates, such as glycoproteins, glycolipids, and proteoglycans, play 
a key role in regulating various cellular events and in the maintenance of 
homeostasis in the tissues. Their biochemical and biological properties 
depend strongly on the specific structure of the glycan portion. Consequently, 
impairment of glycan biosynthesis can have dramatic effects on the 
biosynthesis, function, stability and turnover of each glycoconjugate 
molecule [61].  
In mammals, glycosylation is one of the most common and complex post-
translational modifications of proteins that involves approximately 250 gene 
products [62]. It is affected by a multitude of factors, including the activity of 
the enzymes devoted to the sugar chain initiation and elongation 
(glycosyltransferases and some glycohydrolases), the availability of 
nucleotide sugars (which act as donors of the monosaccharide units in the 
glycosyltransferase-catalyzed reactions), and the kinetics of glycoconjugate 
transport [60]. Altogether, the high-coordinate network of glycosyltranferases  
and the competition between these enzymes for acceptor intermediates 
during glycan elongation [59], define the structural variability of glycans [63]. 
Deficiency of glycosylation enzymes or transporters results in impaired 
glycosylation, and consequently in the pathological modulation of many 
physiological processes [62], including the acquisition of malignant features 
by cancer cells [64]. Regarding that, various studies in the gastrointestinal 
tissues have identified alterations of glycosyltransferase mRNAs that lead to 
the biosynthesis of specific glycan epitopes potentially involved in 
carcinogenesis and cancer progression [64, 65]. 
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1.2.2 Biosynthesis of type 1 chain Lewis antigens in normal and 
malignant gastrointestinal tissues 
As mentioned above, the neoplastic transformation is often accompanied by 
alteration in protein and lipid glycosylation that implies changes in the 
expression of cell surface components, including antigens of the so called 
Lewis histo-blood group. 
Lewis antigens are in fact oligosaccharide determinants (3-5 sugar residues) 
constituting the end of various carbohydrate chains of glycoproteins and 
glycolipids present on cell surface of epithelia, endothelia and erythrocytes 
[66].     
Expression of these carbohydrate antigens is complex and involves 
coordinated activity of multiple glycosyltransferases and their regulation at 
the genetic, epigenetic and transcriptional level. Aberrant expression of 
Lewis antigens in cancer cells has been widely reported in gastrointestinal 
carcinogenesis.  
Among the terminal or sub-terminal part of many carbohydrate chains, the 
presence of a galactose residue (Gal) linked to a hexosamine is very 
common, especially to N-acetyl-glucosamine (GlcNAc). Since the Gal unit is 
usually the  anomer and can be attached to either the 3– or 4- position of 
GlcNAc, sugar chains are frequently classified as type 1 chain, presenting 
the Gal1-3GlcNAc sequence, or the type 2 chain, having the Gal1-
4GlcNAc sequence instead. Expression of type 1 chain Lewis antigens in the 
gastrointestinal tract requires the concurrent expression of a set of specific 
glycosyltransferases that interact and compete with each other to produce 
the final products [67].  
Their biosynthesis requires the activity of a β1,3 galactosyltransferase 
(usually the enzyme 5, named B3GALT5), which catalyzes the addiction of 
the Gal residue to GlcNAc through the β1-3 linkage typical of these chains. 
The biosynthesis of the type 2 chains requires instead the activity of a β1-4 
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galactosyltransferase [68]. The Galβ1-3GlcNAc end can be further modified 
by an α1,4 fucosyltransferase (commonly the enzyme 3, FUT3) giving rise to 
the minimal trisaccharide structure (Galβ1-3[Fucα1-4]GlcNAc-R) of Lewis a 
antigen (Lea). The Lewis b (Leb) epitope, Fucα1-2Galβ1-3[Fucα1-4]GlcNAc-
R, is formed when the Gal1-3GlcNAc precursor is acted upon by an α1,2 
fucosyltransferase (usually the enzyme 2, FUT2) forming a different 
substrate for the successive action of FUT3, giving rise to the final 
difucosylated tetrasaccharide structure [69].  
The synthesis of sialyl-Lewis a (sLea), the epitope of CA19.9 antigen, 
requires the activity of another enzyme activity, an α2,3 sialyltransferase 
acting on galactose (commonly the enzyme 3, ST3GAL3) that transfers sialic 
acid to the Gal residue of the type 1 chain in an α2,3- linkage, resulting in the 
synthesis of the sialylated precursor NeuAc-α2-3Galβ1-3GlcNAc (sialyl-
lacto-N-biose). Subsequently, FUT3 transfers fucose to such precursor 
completing the NeuAc-α2-3Galβ1-3[Fucα1-4]GlcNAc structure of sLea. As 
mentioned above, substitution of GlcNAc by a β1,4-linked galactose leads to 
N-acetyllactosamine, the basic unit of the type 2 chains. The α2,3-sialylation 
of the type 2 chain, followed by the addition of an α1,3-linked fucose, leads 
to the biosynthesis of sialyl Lewis x (sLex) antigen, an isomer of sLea of 
important biological functions [70] (Figure 7). 
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FIGURE 7: Schematic representation of Lewis blood group related antigens. The 
substitution of a GlcNAc residue by a β1,3-linked Gal residue, catalyzed by B3GALT5, 
originates Type 1 chains, whereas substitution with a β1,4-linked Gal residue forms type 2 
chains. The α2,3-sialylation of type 1 or 2 chains, followed by the addition of α1,4- or α1,3-
linked fucose, respectively, leads to the biosynthesis of sialyl Lewis a and sialyl Lewis x 
antigens, respectively. The α1,2-fucosylation of type 1 or 2 chains, followed by the addition of 
α1,4- or α1,3-linked fucose, respectively, leads to the biosynthesis of Lewis b and  Lewis y 
antigens, respectively. 
1.2.3 Role of glycosyltransferases in regulating expression of sLea 
The role of FUT2 and FUT3 is known through in vitro studies [71, 72] and 
well established in vivo by the relevant effects of their polymorphisms in the 
human population [73, 74]. It has been amply demonstrated that there are 
null alleles for FUT3 and FUT2, and their genomic dosage does affect the 
amount of individual antigens expressed, including circulating CA19.9, as 
reported [67, 74]. In particular, individuals who genetically lack the FUT3 
enzyme (FUT3-/-) are known to lack any type 1 chain Lewis antigen, while 
FUT3+/+/FUT2-/- individuals are candidate for higher expression of CA19.9 
than FUT3-/+/FUT2+/+ individuals. The major expression of CA19.9 in subject 
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lacking FUT2 seems to depend on the competition for the precursor 
substrate between FUT2 and ST3GAL3 that initiate the synthesis of the two 
antigens, sLea and Leb, along mutually exclusive pathways [67]. In the colon, 
the expression of ST6GALNAC6 reduces the levels of sLea giving rise to 
disialyl-Lea [75]. 
While the fucosyltransferases have been extensively characterized, there 
are not a lot of information concerning the role of ST3GALT3 in the 
biosynthesis of sLea in gastrointestinal tract. Currently, few in vitro studies 
reported a preferentially action of the enzyme on type 1 disaccharides 
(Galβ1-3GlcNAc, the backbone of sLea antigen) [76] and a high correlation 
between its activity and the expression of the sLea epitope. In particular, 
overexpression of ST3GAL3 leads to an increase of the sLea levels, 
confirming its potential role in the biosynthesis of sLea antigens found on 
glycolipids and glycoproteins. Although it has been shown that ST3GAL3 
expression correlates with tumor malignancy in several carcinomas 
(including those of the extrahepatic bile ducts, breast, cervix, colon, stomach 
and pancreas [77]), its mechanistic role has been not yet fully evaluated. 
Since its cloning in 1999, B3GALT5 was proposed as the most probable 
candidate participating in the synthesis of the sLea epitope in gastrointestinal 
and pancreatic cells [78]. Overall, several studies suggest a down-regulation 
of the biosynthesis of the type 1 chain in colon cancer. This assumption is 
founded on experimental evidence found in colon cancer [79, 80], including 
up regulation of lactosaminic chains [81] and of their biosynthetic enzymes 
β1,4-galactosyltransferase I [82] and -IV [83], and down-regulation of the 
B3GALT5 [78, 84], indicating a switch towards the synthesis of type 2 chains 
in the malignant transformation of colonic tissues. Moreover, the impairment 
of B3GALT5 using anti-sense DNA caused a down-regulation of sLea and 
up-regulation of sLex and lactosaminic chains in a pancreatic cancer cell line 
[85]. Recent data from our lab, demonstrated that in cancer cell lines 
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synthesizing CA19.9, the amount of antigen secreted is proportional to that 
expressed on the cell surface, and depends on appreciable levels of 
B3GALT5. In fact, B3GALT5 is so strongly down-regulated in colon cancer 
that the antigen could not be detected in cancer specimens, or is more 
difficult to detect than in the normal mucosa. Conversely, it is widely reported 
that its concentration is elevated in the sera of patients affected by various 
cancers of the digestive organs, including the colon. Such controversial 
issues open questions about the biology and the origin of circulating CA19.9. 
 
1.2.4 Implication of sLea and related Lewis antigens in tumorigenesis: 
past and current evidences 
The notion that CA19.9 is present in various normal secretions, including 
seminal fluid, bile, and pancreatic juice, has been known for several years.  
However, after the discovery that sLea (and sLex) act as E-selectin ligands, 
the interest about the expression of sialyl Lewis antigens on cancer cells 
increased enormously [69]. In fact, the tumor cells may employ the trafﬁcking 
mechanisms utilized by leukocytes to target distant sites as a tool favoring 
metastasis [86]. This process includes their detachment from the primary 
tumor, passage into the bloodstream, and adhesion to vascular endothelia 
prior to extravasation [87]. 
Tethering and rolling require interactions between the cell adhesion 
molecules E-selectin and their ligands such as sLea and sLex carbohydrates 
[71] (Figure 8). 
Thus, sLea and sLex expressed on cell surfaces could play functional roles 
in the adhesion of malignant cells to the endothelium facilitating the 
extravasation of the cells from the bloodstream and promoting cancer 
metastasis, mimicking neutrophils in inflammation [88-91]. 
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FIGURE 8: Schematic representation of the multi-step process of hematogenous 
metastasis of cancer [88].  
 
The expression and even up-regulation of sLea on the cell surface of cancer 
cells was postulated upon the discovery of another glycosyltransferase, the 
N-acetylgalactosamine α 2,6 sialyltransferase enzyme 6 (ST6GALNAC6), 
able to form disialyl-Lewis a and silenced in colon cancer [75, 92] (Figure 9). 
According to studies published about a decade ago, impairment of 2-6 
sialylation at the GlcNAc moiety occurs during malignant transformation of 
colonic epithelial cells and leads to the loss of the disialyl Lewis a 
determinant, causing a concurrent increase of the sLea determinant in colon 
cancer cells [75]. As hypothesized, the disialyl Lewis a was expressed 
preferentially in the normal epithelium of the colon, mediating normal 
interaction with intramucosal lymphoid cells, while sLea was considered a 
product of the tumor cells potentially involved in hematogenous metastasis. 
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FIGURE 9: Biosynthesis of type 1 chain Lewis antigens in epithelial cells of the 
gastrointestinal tract. Enzymes (underlined) are named according to the HUGO gene 
nomenclature committee. 
 
Coherently with previous findings, immunohistochemical studies revealed an 
abundant reactivity with the anti-CA19.9 antibody in colon and pancreatic 
cancer tissues [93, 94]. These observations lead to the speculation that sLea 
and cognate CA19.9 antigen were a rather specific product of cancer cells 
[93-96]. Otherwise, Lea and Leb have always been considered products of 
normal epithelia of the gastrointestinal tract [97].  
However, a finding contradicting such view was reported in a study aimed at 
elucidating the malignant properties of colon cancer cells expressing sLea 
[66]. Analyzing xenografts obtained in nude mice using anti CA19.9 antibody 
by immunohistochemistry (IH), it was found that mouse tissues were stained 
although they lack any type 1 chain Lewis antigen because no α1,4 
fucosyltransferase is present in mice [98]. These observations suggest that 
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the1116-NS-19-9 antibody does not recognize the antigen by IH, but other 
unknown structures that could be expressed in normal mouse tissue as well 
as in normal and cancerous human tissues. As a very relevant consequence, 
it appeared possible that the cellular and tissue distribution of the antigen 
detected so far by IH could be unreliable.  
1.3 DNA Methylation and Cancer 
1.3.1 Epigenetics and glycosylation 
The term 'epigenetics' literally means 'outside conventional genetics' and is 
commonly used to describe the regulation of gene expression by 
mechanisms that do not involve changes in the DNA sequence [99]. 
The epigenetic regulation is involved in various physiological functions 
including cell division, differentiation, and apoptosis [100], thus it is 
necessary that the whole epigenetic machinery function properly. The 
epigenetic mechanisms are regulated in such a sophisticated fashion that 
disruption of the balance between genetic and epigenetic information, either 
at the genome scale or even restricted to a certain gene, is usually the cause 
of many diseases, including cancer [101, 102].  The epigenetic alterations 
frequently found in cancer include aberrant DNA methylation, abnormal 
histone modifications, and altered expression levels of various noncoding 
RNAs [103]. The very first case was documented in 1983 when researchers 
found an aberrant level of DNA methylation in the tissues of colorectal cancer 
patients [104]. Since then, a growing number of studies have demonstrated 
the contribution of abnormal DNA methylation to human diseases.  
A variety of glycogenes is regulated by epigenetic mechanisms [105], but at 
present, there have been few studies addressing the epigenetic mechanisms 
of glycosyltransferase expression. They include the fucosyltransferase FUT3 
[106], the sialyltransferases ST3GAL6 [107] and the galactosyltransferases  
B4GALT1 [108] and  B3GALT5 [109]. 
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1.3.2 Gene expression regulated through DNA methylation  
DNA methylation is a fundamental epigenetic modification in mammalian 
cells and occurs at the 5 position of the cytosine rings in the dinucleotide 
sequence CG in vertebrates [110].  
Until recently, the majority of DNA methylation studies focused on the 
analysis of CpG islands associated to promoter regions. There are 
approximately 20,000 CpG islands in the mammalian genome [111] 
representing 5% of all CGs and 1% of the genome. CpG islands usually 
consist of stretches of DNA that have very high frequencies of CGs 
dinucleotide repeats, occupying approximately 60% of human gene 
promoters [110].  
Genome wide DNA methylation profiling studies show that there is a strict 
correlation between promoter DNA methylation and promoter activity 
depending on the CpG density of the promoter [112] (Figure 10). According 
to these recent evidences, high CpG content promoters (HCPs) are globally 
unmethylated or hypomethylated even when the promoter is inactive [112]. 
HCPs are often associated with housekeeping genes, and genes with more 
complex expression patterns such as those expressed during embryonic 
development [113]. The expression pattern of genes with intermediate CpG 
content promoters (ICPs) is commonly inversely correlated to the degree of 
methylation [112]. In contrast, it seems that DNA methylation at low CpG-
density promoters (LCP) is not correlated with transcriptional silencing, and 
indeed most LCPs are methylated irrespective of their expression state [114], 
suggesting that other mechanisms regulate the activity of LCPs. Highly 
tissue-specific genes are considered to belong to this class of promoters 
[113]. Overall, these results indicate that HCPs remain unmethylated 
regardless of transcriptional activity, ICPs are repressed when methylated 
and LCPs are usually methylated. 
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FIGURE 10: Distribution and roles of 
DNA methylation. The distribution of 
DNA methylation varies according to 
genomic landmarks. High-CpG density 
promoters (HCP) are usually 
hypomethylated, intermediate CpG-
density promoters (ICP) are usually 
methylated, and low CpG-density 
promoters (LCP) can be either 
methylated or unmethylated (the 
methylation does not correlate with 
repression).  
Figure extracted and modified from [115]. 
 
 
 
The best-studied epigenetic alteration in cancer is the methylation that occur 
within CpG islands present in 70% of all mammalian promoters [116]. 
Experimental evidences have shown that about 5%–10% of unmethylated 
CpG islands in a promoter becomes abnormally methylated in several cancer 
genomes [116], and many studies have investigated the mechanisms that 
underpin this relationship. Two main models have emerged (Figure 11). In 
one model, methylation causes a physical hindrance of transcription factor 
binding to their recognition motifs, inhibiting transcription. A second model 
involves the recruitment of transcriptional corepressor complexes mediated 
by methyl CpG-binding domain protein (MBD) that recognizes methylated 
DNA [117]. In particular, binding of MBD protein to the methylated DNA may 
physically block the binding of transcription factors to the promoter region, 
repressing transcription initiation. Alternatively, binding of MBD protein to the 
methyl CpG regions leads to a cascade of downstream events, including 
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recruiting of repressors and other proteins that mediate histone modifications 
and induce chromatin remodeling, blocking the access of transcription 
factors to the promoter region [118].  
 
 
FIGURE 11: Model of DNA methylation-mediated gene silencing [118]. (A) Methylation of 
the cytosine of the CpG dinucleotides in a gene promoter region within a transcription factor’s 
binding consensus sequence motif may be recognized by the transcription factor (TF) as a 
“mutation” and thus results in loss of TF binding and transcription initiation. (B) Methyl-CpGs 
may recruit MBD protein binding to the methylated DNA region in a gene promoter region. 
The MBD proteins may physically block TF binding to the promoter region or recruit repressors 
to inhibit TF activity and thereby silencing gene transcription. 
 
While the strong association between CpG island hypermethylation and 
gene silencing in cancer has been widely documented and characterized, 
the role of the hypomethylation of the other CpG dinucleotides in cancer has 
not yet been established well.  
However, the general dogma that DNA methylation equates with 
transcriptional silencing has recently been questioned by genomewide DNA 
methylome studies. In fact, these studies have shown that many 
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transcriptionally active genes present high levels of DNA methylation within 
the gene body and at the so called CpG island ‘‘shores” [116].  
The term CpG island shores refers to regions of lower CpG density that lie in 
close proximity (~2 kb) of CpG islands [119] and are reported to be 
methylated in a tissue-specific manner [120, 121].  
Overall, although DNA methylation is typically considered to be involved in 
silencing mechanism, tissue specific low CG content promoters are 
methylated irrespective of their expression. This aspect can be explained by 
two mechanisms. One possibility is that the CG methylation of such 
promoters creates transcription factor binding sites, the other is that low CG 
content promoters can be associated with some distal enhancer containing 
high CG regions. Differential methylation of these enhancer regions might be 
the regulator for the transcription of these genes [114]. 
 
1.3.3 Gene body methylation 
Gene body methylation is common in ubiquitously expressed genes and is 
positively correlated with gene expression [122]. It has been proposed that it 
might be related to elongation efficiency and prevention of spurious initiations 
of transcription. In general, DNA methylation is thought to block transcription 
initiation but not elongation. In fact, intragenic nucleosomes with 
trimethylation of H3K36, which is associated with transcript elongation, 
seems to recruit DNA methyltransferases, thus facilitating the methylation of 
intragenic DNA [123]. Despite alternative promoters are classically located 
upstream of the translation start site, some of them are also present within 
genes. Therefore, it seems that a major function of the tissue-specific and 
conserved intragenic methylation may be to regulate the activity of such 
alternative promoters and to interfere with expression of the main transcripts 
[124, 125]. An interesting study observed a context-dependent correlation of 
CpG gene-body methylation, related to whether the CpGs were located 
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inside or outside intragenic CpG islands. For CpGs outside intragenic CpG 
islands, the methylation status correlated positively with gene expression, 
while for CpGs located within CpG islands, the methylation status can be 
either positively or negatively correlated with gene expression levels [126].  
1.3.4 Collaborative model for DNA methylation 
Recently, a new model has been proposed for DNA methylation, named the 
“collaborative” model. This innovative model is based on the collaboration 
between CpG sites, so that the methylation reactions at one site are affected 
by the methylation status of the nearby CpGs [127]. This can be achieved by 
means of systems with positive feedback. Thus, the probability that a CpG 
becomes or remains methylated increases if other CpGs in the cluster are 
methylated. Conversely, the probability that a CpG becomes or remains 
unmethylated increases if the CpGs in the cluster are unmethylated. In the 
collaborative model, the generated systems are sensitive to CpG density 
[127] and to the separation between CpGs [128] (Figure 12). The bias toward 
hyper-methylation for less dense CpG clusters suggests that collaborative 
methylation reactions generally act more efficiently than collaborative 
demethylation reactions over longer CpG–CpG distances. Conversely, the 
bias toward hypo-methylation for more dense CpG clusters suggests that 
collaborative demethylation reactions are favored at shorter CpG–CpG 
distances [128].  
33 
 
FIGURE 12: Collaborative model design. The 
probability of interaction between a target CpG 
and an enzyme (methylase or demethylase) 
recruited to a mediator CpG is dependent on 
the DNA distance between the two CpG sites. 
Moreover, hyper-methylated CpGs (low density 
of CGs) are associated with a large zone of 
increased methylation, while hypo-methylated 
CpGs (high density of CGs) seem to have 
effects over short distances only. Thus, the 
collaborative methylation is more efficiently 
over long distance than collaborative 
demethylation. The low CpG density outside 
islands is likely to strongly disfavor the 
collaborative demethylation reactions that are 
thus restricted to CpG islands.  
Figure extracted and modified from [128]. 
 
 
 
1.3.5 B3GALT5: expression mechanisms 
In 1999, the B3GALT5 cDNA was first cloned from the human colon 
adenocarcinoma cell line COLO-205 by Isshiki et al. 
Studies on the B3GALT5 gene showed that at least two main promoters drive 
expression of alternative transcripts differing in their 5' untranslated region 
(UTR) [129]. In mammary gland, thymus, and trachea, as well as in some 
human cancer cell lines, transcription is mainly driven by the native 
promoter, which is conserved through mammalian evolution. It is sensitive to 
the ubiquitous transcription factor NF-Y [130] and is epigenetically regulated 
through the methylation of two flanking CpG islands [131] (Figure 13).  
In the organs of the gastrointestinal tract (such as colon, stomach and 
pancreas), is active another promoter, named LTR, which represents a long 
terminal repeat of retroviral origin inserted about 25–30 million years ago 
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(Figure 13). This alternative promoter is present only in primates following 
the division of Old World monkeys [132]. It is stronger than the native 
promoter and is sensitive to HNF1α/β transcription factors [79], which are 
necessary but not sufficient to drive expression of the transcript [79, 129]. 
A complex interplay of epigenetic mechanisms modulates the expression of 
B3GALT5 from both promoters, leading to a strong downregulation in colon 
cancer. The methylation status of both CpG islands flanking the native 
promoter is increased in cancer, leading to the inhibition of B3GALT5 
expression [131]. Conversely, Zulueta and coworkers have recently shown 
that treatment with a demethylating agent inhibits the B3GALT5 LTR 
promoter, reproducing in vitro the down-regulation of the transcript observed 
in cell lines and colon cancer specimens [133]. Therefore, although HNF1-
α/β transcription factors are necessary to activate the B3GALT5 LTR, 
transcription modulation seems to depend on unknown regulatory elements 
that are active when methylated [133]. 
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FIGURE 13: Genomic structure and DNA methylation of the human B3GALT5 gene. In 
the upper part, the genomic sequence of chromosome 21 (0.26 Mbp) encompassing 
B3GALT5 and intergenic regions is presented together with the positions of the exons and the 
LTR transposon. In the lower part, the  enlarged region show transcription factor binding sites, 
CpG islands (CGI, in red), CpG short islands (CGsI) of at least 100 bp (pink), CG dinucleotides 
present in the LTR transposon and the two main transcripts [109]. 
 
The B3GALT5 gene offers an emblematic example of the role of differentially 
methylated CpG sites in regulating gene transcription. In fact, the concurrent 
methylation of the CpG islands nearby the native promoter and the 
demethylation of distant regulatory elements, determine gene silencing in 
colon cancer.  
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2. AIMS 
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Our working hypothesis is that the sLea epitope of CA19.9, as well the other 
type 1 chain antigens Lea and Leb, are all down-regulated in gastrointestinal 
adenocarcinomas due to the epigenetic silencing of B3GALT5. According to 
our model, elevation of circulating sLea in cancer is thus paradoxical. Such 
a hypothesis relies on recent published data and our preliminary results 
showing how a pitfall occurred in the past with IH detection, leading to the 
wrong assumption that CA19.9 was synthesized by tumor cells. In addition, 
since elevated levels of circulating CA19.9 are reported also in benign 
conditions, we hypothesize that the circulating antigen could be secreted by 
the healthy glandular ducts. In cancer, the obstruction of the ducts impairs 
secretion and determines the reabsorption of the molecules (i.e. mucins) in 
the bloodstream. In order to confirm our working hypothesis and clarify the 
doubts regarding the current concept of CA19.9 as a tumor marker, our study 
is aimed at defining: 
 the actual distribution of sLea and related Lewis antigens in pancreas and 
colon cancer, by immunofluorescence staining of sections prepared from 
cancer specimens and surrounding normal tissue in order to understand 
whether or not the circulating antigen is produced by cancer cells. 
 The expression levels in the corresponding tissue of cognate 
glycosyltransferase transcripts involved in the synthesis, determined by 
real time PCR. 
  The status of the chromatin affecting the main B3GALT5 promoters, 
defined by bisulfite sequencing and ChIP analysis performed on both cell 
lines and selected cancer specimens.   
 What is the distant DNA region recruited by the transcription machinery of 
the B3GALT5 LTR promoter that boosts transcription, and to prove the 
inhibitory effect of its demethylation.   
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3. MATERIAL AND METHODS 
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3.1 Cell and tissue processing 
COLO-205 (colon cancer), MKN‐45 (gastric cancer), Huh-7 
(hepatocarcinoma), MDA-MB-231 (breast cancer), MDA-MB-231/ HNF1α (a 
clone expressing HNF1, [133]), BxPC-3 and Capan-2 (both pancreatic 
cancer) cell lines were grown and treated with 5AZA (5’-aza-2'-
deoxycytidine) as previously reported [85, 133]. Six human colon and two 
human pancreas samples were collected at surgery as reported [130]. A 
matched pair of RNAs from cancer and adjacent normal pancreas (Ambion) 
and two RNAs from normal pancreas (Clontech and Stratagene, 
respectively) were of commercial origin. Specimens of tumor and adjacent 
normal tissue (about 80 mm3 each) were immediately frozen in dry ice and 
kept at −80 °C. Frozen material was cut in aliquots (about 20 mm3) that were 
thawed and used as follows. For RNA extraction, samples were 
homogenized in 0.14 ml lysis buffer (ReliaPrep RNA miniprep system, 
Promega) using a rotary homogenizer (UltraTurrax) and processed 
according to the manufacturer's protocol, including DNAse treatment. Elution 
was done with 30 μl of nuclease free water heated at 70 °C. For genomic 
DNA extraction, samples were treated with 0.2 ml of buffer ATL (QIAamp 
DNA Mini Kit, Qiagen) containing 2.0 mg/ml proteinase K at 60 °C overnight, 
and then processed according to the manufacturer's protocol. For total lysate 
preparation, samples were homogenized (Ultra Turrax) in PBS containing 
Halt protease inhibitor cocktail (Thermofisher) and then brought to RIPA 
buffer (50 mM Tris-HCl pH 7.4, 1% Nonidet-P40, 0.5% Na-deoxycholate, 
0.1% SDS, 150 mM NaCl) containing protease inhibitor cocktail, and kept on 
ice with frequent vortexing for 1 h. After spinning at 12.000 ×g for 10 min at 
4 °C, the clean supernatant was removed and stored at −80 °C. Nuclear 
protein was extracted as reported [131]. Nucleic acid concentrations were 
determined using the Qubit fluorometer (Thermofisher) and protein was 
measured with the Bradford method. 
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3.2 Reverse transcription quantitative real-time polymerase 
chain reaction (RT-qPCR) 
First strand cDNA was synthesized from 1 to 4 μg of total RNA by Moloney 
Murine Leukemia virus reverse transcriptase as reported [133]. Control 
reactions were prepared by omitting the reverse transcriptase. cDNAs (0.2–
1.0 μl of first strand reactions) were amplified in a volume of 20 μl using Sybr 
Premix Ex Taq (Tli RNase H Plus) (Takara), ROX as reference dye and Step 
One Plus instrument (Applied Biosystem Life Technologies). Primer 
sequences are reported in Table 2. Annealing temperature was 60 °C. The 
amounts of amplified target cDNAs were calculated from their respective 
standard curves and normalized by those for GAPDH. 
 
 
B3GALT5 NATIVE 
Forward  5’-GGGCTGCCCCGCGCAC  
Reverse  5’CACAGTGTAAATGCCAAGAGGA  
B3GALT5 LTR 
Forward  5’-CTGGCCTTTGGACCCGAG  
Reverse  5’-CACAGTGTAAATGCCAAGAGGA  
ST3GAL3 
Forward  5’-CTCTGGGGTCACGAATTGAC  
Reverse  5’-TGCTCAGGCCGCTGCATG  
  TABLE 2: PCR primers for quantification of specific transcripts. 
 
3.3 Dot-blot and western blot analysis 
Serial dilutions of total lysates were prepared in water to obtain 80 μl aliquots 
containing 0.03 to 4 μg of protein, which were applied to a nitrocellulose 
membrane using a 96-well blotter (BioRad), washed with 0.4 ml water and 
air dried. Membranes were blocked 30 min at RT with 5% defatted milk in 
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PBS containing 0.1% Tween-20 (PBS-T), washed 3-times with PBS-T, and 
incubated at 4 °C overnight with 0.5 μg/ml of each of the following 
monoclonal antibodies: anti-CA19.9 (NS-1116-19-9, ATCC hybridoma HB 
8059), anti‐Leb (130–3-F7–5, ATCC hybridoma HB 8325), anti-Lea (151–6-
A7–9, ATCC hybridoma HB 8324), which were purified from the respective 
culture media as reported [68, 84]. 
Cell pellets and surgical specimens were processed to obtain nuclear 
extracts using a commercially available kit (NE-PER, Thermofisher) as 
reported [131]. Aliquots of nuclear extracts (5–20 μg of protein) were 
separated by 8% SDS-PAGE, transferred to a nitrocellulose membrane 
(Trans-Blot SD Semi Dry Transfer Cell, Bio\\Rad Laboratories) and blotted 
with rabbit polyclonal anti‐HNF1α/β (sc-8986, 1:200, Santa Cruz 
Biotechnology) or rabbit polyclonal anti-NF-YA (sc-10779, 1:200, Santa Cruz 
Biotechnology) according to our published protocol [134]. 
3.4 Bisulfite sequencing 
Genomic DNA (0.1–1.5 μg) was submitted to bisulfite treatment and 
purification using the Epitect bisulfite Kit (Qiagen). For cloning, the obtained 
material was amplified by PCR as follows. Amplifications (35 cycles) were 
performed in 25 μl using a hot-start Taq (Promega) according to the 
manufacturer's recommendations in the presence of an enhancer (PCRx 
Enhancer system, Invitrogen) with 2 μl of bisulfite converted DNA as template 
and first reaction primers (Table 3). Amplification program included a single 
treatment at 94 °C for 3 min followed by cycles consisting of 1 min at 94 °C, 
1 min at 58 °C, and 1 min at 72 °C, and a final extension step at 72 °C for 8 
min. Nested PCRs (25 cycles) were performed in a final volume of 50 μl using 
1–2.0 μl of the PCR products and inner primers designed to contain 
restriction sites (Table 3). Reaction mixtures and amplification programs 
were as above described, but annealing temperature was 62 °C. Amplified 
fragments were column-cleaned, digested with appropriate restriction 
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enzymes, column-cleaned again, and cloned into pGl3 or pCDNA3 vectors 
for sequencing (at Eurofins sequencing service). 
 
Region 1 
First reaction 
forward 5’-GTTTTAGGTTAGGTTTAAGGTAAGG 
reverse 5’-CTACCTCCAAACACATCTAAACC 
 
Second reaction 
forward 5’-CGCGAAGCTTTGGTTTGGGGAGAGTTTTAGG 
reverse 5’-CGCGTCTAGATAAACAAACAAATAAATAAAAAAAAATTTC 
Region 2 
First reaction 
forward 5’-GGTTAGGGGTAGGTTTAGGTTTG 
reverse 5’-CAATAACCAAACCCCACTATAAAACC 
 
Second reaction 
forward 5’-CGCGAAGCTTGGAAAAGAAAATAGTAGAGGTGAG 
reverse 5’-CGCGTCTAGACAAAAAATCTCCAAAAACTATAACCC 
Region 3 
First reaction 
forward 5’-GGAAAATAGGGTTTTAATATTATAGTG 
reverse 5’-CAATTCTAACCCCCACATCAATC 
   
Second reaction 
forward 5’-GCGCAAGCTTAATTTTTGAGATGGAGTTTTATTTT 
reverse 5’-GCGCTCTAGAATACAAACAACTTCTTATAACTTAC 
TABLE 3: Primers for nested PCR after bisulfite treatment. Restriction sites for cloning 
are underlined. 
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3.5 ChIP assay 
Chromatin was prepared from about 107 cells and immunoprecipitated using 
a commercially available kit (SimpleChIP, Cell Signaling) with the 
modifications reported [131]. About 1 μg of chromatin DNA, determined by 
fluorometry upon reversing cross linking (Qubit, Invitrogen), diluted to a final 
volume of 0.25ml, was used for each immunoprecipitation. Aliquots (10–20 
μl) were kept as input DNA. Antibody binding reactions were performed at 4 
°C overnight under rotation. 
Precipitation with agarose-bound G-protein, washing, elution, reverse of 
cross-linking, and DNA purification were performed with the kit reagents 
according to the manufacturer's protocol. The following antibodies were 
used: anti‐rabbit IgG, 1 μl (Cell Signaling); anti-trimethyl-Histone H3 (Lys4), 
named H3K4me3, 2 μl (GeneSpin, PAb005); anti-trimethyl- Histone H4 
(Lys20), named H4K20me3, 2 μl (Millipore #07–749); antiacetyl- Histone H3, 
named H3KAc, 1 μl (Millipore #06–599). To quantify the immunoprecipitated 
DNA, qPCR was performed using specific primers (see Table 4 for 
sequences). Reaction mixture, 20 μl, and amplification conditions were as 
above described for RT-PCR. 
HNF1-binding region 
Forward  5’- TCATGAGTTACAGAGCAAAGCC  
Reverse  5’- GCCCACTGACTCACAGCCAATC  
Region 2 
Forward  5’- TCAAGGACCAGTGCAGATGC  
Reverse  5’- GCTCAAGGG GTCTCCAGG  
Region 3 
Forward  5’- TGCCTGGCCAACATCACATG  
Reverse  5’- CCA GGA CCT GTC GCT CAC  
TABLE 4: Primers for qPCR after ChIP. See Figure 23 for primer location in the 
genome sequence. 
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3.6 Immunofluorescence and immunohistochemistry 
IF and IH were performed on two primary colon and pancreas 
adenocarcinoma samples collected from the archive of the Unit of Human 
Pathology of the San Paolo Hospital Medical School, University of Milan. 
Archival material was used in compliance with the national guidelines and in 
respect to the privacy of the patients. IF was performed on formalin-fixed 
paraffin-embedded 4 μm thick tissue sections as previously reported [135]. 
Sections were deparaffinised in xylene and rehydrated through a graded 
series of alcohols. Primary antibodies were those above reported for dot 
blotting, and were used at the following concentrations: anti-CA19.9, 0.4 
μg/ml; anti-Lea 1 μg/ml; anti-Leb 1 μg/ml. Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/FITC (Dako, dilution 1:80) was used as fluorophore-
conjugated secondary antibody. Nuclei were subsequently counterstained 
with DAPI (Invitrogen). Serial dilutions of primary antibodies were tested on 
positive and negative controls and on a colon sample to assess the effect of 
antibody concentrations (Figure 14 and 15). Immunohistochemical studies 
were carried out on formalin-fixed paraffin-embedded 4 μm thick tissue 
sections as previously reported [66], with the anti-CA19.9 antibody only, used 
as for IF. Antigen retrieval was performed at 97.5 °C for 35 min in 9 mM  
sodium citrate at pH 6.0. Endogenous peroxidase activity was quenched with 
3% H2O2 for 10 min. Staining was performed with 3,3′ diaminobenzidine as 
chromogen for 8 min and slides were counterstained with hematoxylin. The 
reaction was detected with the autostainer (Optimax i6000, Biogenex) by 
Novolink Max polymer detection system (Novocastra Laboratories). Slides 
were immunostained in the same batch, to prevent incubation variability and 
to ensure identical condition for comparison. Slides with absence of the 
primary antibody were also included as negative controls. Images of 
hematoxylin/eosin (H&E) staining, immunohistochemical staining and IF 
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staining were obtained using the digital slide scanner NanoZoomer 2.0 
(Hamamatsu Photonics, Japan). 
 
FIGURE 14: Detection of CA19.9 in colon sections using serial dilutions of the NS-1116-
19-9 antibody. Sequential sections from a colon cancer sample were studied by IH or IF at 
the indicated antibody dilutions. For IF detection, nuclei were blue-counterstained with DAPI 
as a reference. Upper part: sections showing neoplastic transformation are presented at lower 
magnification (scale bars 2.5 mm). Lower part: sections showing normal mucosa architecture 
are presented at higher magnification (scale bars 0.25 mm). 
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FIGURE 15: Detection of Lewis a and Lewis b antigens by IF using serial dilutions of 
the antibodies. Sections from two xenografts were studied by IF at the indicated antibody 
dilutions and nuclei were blue-counterstained with DAPI as a reference. Scale bars = 0.25 
mm. HCT-15 denotes the negative control. It is a xenograft obtained inoculating mice with the 
human colon carcinoma cell line HCT-15 that lacks type 1 chain Lewis antigens due to the 
absence of B3GALT5 enzyme. HCT-15-T5 denotes the positive control. It is a xenograft 
obtained inoculating mice with a recombinant clone that expresses type 1 chain Lewis 
antigens upon transfection of B3GALT5 cDNA. Both xenografts were characterized in a 
previous report [66]. 
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4. RESULTS 
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4.1. Detection of Lewis antigens in colon and pancreas samples 
by IF on tissue sections 
To investigate the actual expression of CA19.9 in human gastrointestinal 
cancers, we analyzed two pairs of colon and pancreas samples by IF with 
antibodies against type 1 chain Lewis antigens. In both the colon samples 
there was high expression of Lea in the portion of the section where the 
normal architecture of the mucosa was well preserved (Figure 16 B and C), 
which disappeared in the cancerous part (Figure 16 D). CA19.9 and Leb 
were also lacking in this part, while they presented a spotted reactivity 
scattered through the preserved normal mucosa of the section (Figure 16 B, 
C and D). We also tried detection of CA19.9 on the same sections by IH. It 
is noteworthy that the NS-1116-19-9 antibody did reveal ambiguous CA19.9 
reactivity. In fact, the antibody apparently detected the antigen where no 
Lewis antigen, or Lea but not CA19.9, was present as revealed by IF. (Figure 
16). In the case of the pancreas, the features of the two analyzed samples 
were different from each other. In fact, by IF one reacted mostly with Leb 
(Figure 17), while the other mostly with CA19.9 (Figure 18). In both cases, 
reactivity was evident in the part of the sections where the glandular 
architecture was recognizable, and it was restricted to the pancreatic ducts 
(Figures. 17 B and 18 B). In the less differentiated part of the sections, the 
reactivity was not present in the bulk of the tumor cells, but restricted to ducts 
or ductal-like structures (Figures 17 C and 18 C, D). By IH detection, the 
obtained patterns were misleading. In fact, false CA19.9 reactivity was more 
pronounced in the less differentiated parts of the sections, and very evident 
in those expressing Leb or Lea but not CA19.9 (Figure 17 C). On the other 
hand, in the sections expressing CA19.9, IH sometimes overlapped IF, 
making the picture even more ambiguous (Figure 18 E). These results 
indicated that the data obtained so far by IH are affected by technical 
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artifacts, while IF suggests that the colon and pancreas may present different 
patterns of expression of Lewis type 1 antigens. 
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FIGURE 16: Detection of type 1 chain Lewis antigens in colon sections. A section from the 
colon presenting normal mucosal architecture (left side) or neoplastic transformation (right side) 
was studied by IF with anti-Lea, −Leb and -CA19.9 antibodies, or by IH with anti-CA19.9 antibody. 
For IF detection, nuclei were blue-counterstained with DAPI as a reference. (A) Only H&E staining 
is presented, at the lowest magnification, scale bar=5mm. (B) The area boxed on the left side of 
panel A (normal colon mucosa) is presented at higher magnification after staining with all 
antibodies, scale bar=2.5mm. (C) The area boxed in panel B is presented at the highest 
magnification, scale bar=0.25mm. (D) The area boxed on the right side of panel A (colon cancer) 
is presented at higher magnification, scale bar = 1 mm. Another section from a second case 
provided very similar results and is not presented. 
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FIGURE 17: Detection of type 1 chain Lewis antigens in pancreatic carcinoma sections (first 
case). A section from the pancreas presenting well differentiated (left side) or poorly differentiated 
glandular structure (right side) was studied by IF or by IH as in Figure 16. (A) Only H&E staining is 
presented, at the lowest magnification, scale bar=5mm. (B) The area boxed on the left side of panel 
A (well differentiated architecture) is presented at higher magnification after staining with all 
antibodies, scale bar = 1.0 mm. (C) The area boxed on the right side of panel A (poorly differentiated 
structure) is presented at higher magnification, scale bar= 0.25 mm. 
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FIGURE 18: Detection of type 1 chain Lewis antigens in pancreatic carcinoma sections from 
another case. Sections were studied as reported in Figure 17. (A) Only H&E staining is presented, 
at the lowest magnification, scale bar=10mm. (B) The area boxed on the left side of panel A (well 
differentiated architecture) is presented at higher magnification, scale bar=0.5mm. (C) The area 
boxed on the right side of panel A (poorly differentiated structure) is presented at higher 
magnification, scale bar=1.0mm. (D) The area boxed in panel C is presented at the highest 
magnification, scale bar=50 μm. (E) A section of poorly differentiated structure is presented to show 
the misleading effect obtained by IH that provides partially overlapping results with IF; scale bar = 
0.25 mm. 
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4.2 Detection of glycosyltransferase transcripts and cognate 
Lewis antigens in colon and pancreas tissues 
 
Expression levels of ST3GAL3 and B3GALT5 native and LTR transcripts 
were determined by RT-qPCR in matched normal and cancer specimens 
from the colon and the pancreas, and in pancreatic cancer cell lines BxPC-3 
and Capan-2, known to express Lewis type 1 antigens [136]. As expected 
[79, 131, 133, 137], the main features of B3GALT5 transcripts in the colon 
were the following (Figure 19): first, the high levels of expression in the 
normal mucosa due to the large amounts of the LTR transcript, which was 
higher than the native transcript; second, the strong down-regulation of both 
transcripts in cancer, which made the overall expression of B3GALT5 mRNA 
negligible. In the pancreas (Figure 19), expression levels of B3GALT5 LTR 
transcript were similar to, or even lower than, those of the native transcript, 
without difference between normal and cancer tissues for both transcripts. 
Moreover, B3GALT5 LTR transcript was undetectable in both BxPC-3 and 
Capan-2 cell lines. The levels of ST3GAL3 transcript in both normal colon 
mucosa and colon cancer were low (mean ± SEM, 1.92 ± 0.49 fg/pg of 
GAPDH), while they were significantly higher (8.59 ± 1.73 fg/pg of GAPDH, 
p = 0.006) in pancreas tissues (Figure 19). The high expression levels of 
B3GALT5 LTR transcript in the colon and the cancer-associated silencing of 
B3GALT5 thus appeared to be tissue specific since they were not found in 
the pancreas.  
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FIGURE 19: Detection of B3GALT5 and ST3GAL3 transcripts in colon and pancreas 
samples. Matched pairs representing cancer and surrounding normal tissue from the colon 
and the pancreas were collected at surgery and immediately frozen. The frozen material was 
cut into aliquots that were processed for analysis. Total RNA was extracted, reverse 
transcribed, and amplified by qPCR as described in sections 2.1 and 2.2. Pancreas RNA 
samples 3 (matched pair), 4 and 5 (normal tissue) were of commercial origin.  
Results are the mean ± standard deviation for three determinations. Amounts were calculated 
from a standard curve and normalized to the amounts calculated for GAPDH. N, normal tissue; 
T, tumor. 
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The pattern and amount of Lewis type 1 antigens were determined by dot-
blot staining of lysates available from the same matched pairs of colon and 
pancreas tissues. Lea was found to be very abundant in normal colon 
mucosa, at much higher levels than Leb, and the amount of CA19.9 was the 
lowest in the analyzed samples. In colon cancer, the levels of all Lewis 
antigens were dramatically lower, and CA19.9 was almost undetectable. An 
exception was apparent in colon cancer sample 2, where Leb expression 
was relevant (Figure 20). The data suggest that Lewis antigen expression 
depends in part on glycosyltransferase levels, and in particular that 
B3GALT5 and ST3GAL3 are limiting in the colon for biosynthesis. To verify 
this aspect, we analyzed a further colon cancer sample known to maintain 
residual B3GALT5 transcripts (about one third of the adjacent normal 
mucosa). In this case (Figure 20, colon sample 6), Lewis antigens were 
detectable in the cancer sample, but still at lower levels than in the normal 
counterpart, and the amount of CA19.9 remained the lowest. Expression of 
the antigens in the two pancreas samples was different with respect to the 
colon. The amounts in cancer were higher than in normal tissue, and those 
of CA19.9 and Leb higher than Lea. Pancreas sample 2 expressed much 
more antigen than sample 1. These data suggest that tissue-specific 
expression of glycosyltransferases is responsible for the different levels of 
Lewis type 1 antigens, but other mechanisms affect the total amount of 
antigens present in the tissues, especially in cancer. 
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FIGURE 20: Detection of Lewis type 1 antigens in tissue lysates. Tissue samples are 
those reported in Figure 18. Lysates were prepared in RIPA buffer as described in section 
2.1. Antigens were determined by immunostaining of dot-blots prepared with three amounts 
of sample lysates brought to the same final volume, using monoclonal antibody followed by 
peroxidase-labeled secondary antibody, as described in section 2.3. Labels show the actual 
amount of sample protein blotted. 
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4.3 Regulation of B3GALT5 expression: mechanisms affecting 
the native promoter 
Nuclear proteins were extracted from normal and cancer specimens of 
pancreas samples 1 and 2, as well as from BxPC-3 and Capan-2 pancreas 
cell lines, and analyzed by western blotting. NF-Y was easily detected in all 
specimens, while HNF1α/β was faintly detected in both normal and cancer 
tissues (Figure 21).  
 
 
FIGURE 21: Detection of NF-Y and HNF1 transcription factors in pancreas tissues and 
cell lines. Nuclear extracts (5-20 µg of protein) were separated by 8% SDS-PAGE and 
transferred to a nitrocellulose membrane that was blotted with anti NF-Y or anti-HNF1 
antibodies followed by HRP-labeled secondary antibody and chemiluminescence detection, 
as detailed under section 2.3. N: normal tissue; T: tumor. Parental MDA-MB-231 lacks HNF1 
and expresses the NF-Y doublet corresponding to the long (upper band) and short form (lower 
band) of the factor [131]. MDA-MB-231/HNF1α and MDA-MB-231/HNF1β are recombinant 
clones expressing either form of the factor. All such cells and colon sample 1 were used as 
references. 
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We then determined the methylation status of CpG islands flanking the native 
promoter by bisulfite sequencing of genomic DNA extracted from the same 
pancreas samples (Figure 22). Very low levels of methylation were found in 
both samples, without differences between normal and cancer tissues. In 
particular, the methylation levels were even lower than in the BxPC-3 cell 
line, but comparable with those previously found in Hucc-T1 cells [131], a cell 
line derived from bile ducts known to express the highest levels of B3GALT5 
native transcript. These data indicated that the methylation-dependent 
mechanism of silencing reported in colon cancer [131] appears not to be 
active in the pancreas, and may explain the presence of B3GALT5 native 
transcript and cognate reaction products (including Lewis antigens) found in 
these cancers only. 
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FIGURE 22: Lollipop representation of methylated CG residues in CpG islands 1 and 2 
flanking B3GALT5 native promoter. Genomic DNA extracted from BxPC-3 cells and 
pancreas tissue samples reported in Figures 19 and 20 was submitted to bisulfite treatment, 
amplified through nested PCR, and the obtained fragments cloned as reported in section 2.4. 
Seven independent clones were submitted to direct DNA sequencing and the obtained 
sequences analyzed using BiQ Analyzer software (http://biq-analyzer.bioinf.mpi-sb.mpg.de/). 
Empty circles represent unconserved (unmethylated) cytosines, full circles represent 
conserved (methylated) cytosines. Dots (no circle) represent potential polymorphisms or 
sequencing errors. Twelve out of 15 CG pairs were analyzed for CpG 1, and are shown on 
the left of the thin line; 66 out of 76 pairs were analyzed for CpG 2 and are shown on the right. 
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4.4. Epigenetic regulation of B3GALT5 LTR promoter: 
individuation of a candidate DNA sequence 
No true CpG island flanks the LTR promoter, but instead only stretches of 
spared CG dinucleotides sometimes forming short islands about 100 bp long 
[109]. On this basis, we compared by bisulfite sequencing the status of DNA 
methylation of stretches of CG dinucleotides spaced along the 5′ side of the 
LTR promoter in three cell lines: COLO-205 (LTR transcript: 15.1 fg/pg of β-
actin), MKN-45 (LTR transcript: 3.2 fg/pg of β-actin), and Huh-7, not 
expressing the transcript at all even in the presence of high levels of HNF1 
[133]. In the light of preliminary results, we focused on two DNA regions 
spanning about 1 kb from the LTR promoter, regions 1 and 2 (15 and 24 CG 
residues, respectively (Figure 23).  
 
 
FIGURE 23: Schematic representation of the B3GALT5 gene and DNA regions 
potentially involved in the epigenetic regulation of transcription. DNA size is in Kbp. The 
relative location of the following B3GALT5 exons are drawn approximately to scale: native 
exon 1 A (23 bp), exon −1 (238 bp), LTR exon 1 (273 bp), exon 3 (166 bp), and exon 4 (2328 
bp) that contains the whole coding sequence. Thin vertical bars represent CG dinucleotides 
and the enlargements show true CpG islands (CpGI) and relevant stretches of CG 
dinucleotides (CGs). R1 (1112 bp), R2 (821 bp) and R3 (891 bp), denote DNA regions 1, 2 
and 3, respectively, subjected to bisulfite sequencing and ChIP assay. Transcription factor 
binding sites of both B3GALT5 promoters are indicated by arrows. The blue vertical lines in 
each region indicate the target sequences for ChIP quantification by qPCR. The entire LTR 
transposon (644 bp) present in region 1 is pink-arrowed. 
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Region 1, encompassing the LTR transposon, presented a methylation 
pattern unrelated to LTR transcription (Figure 24). 
 
 
FIGURE 24: Lollipop representation of 
methylated CG residues in DNA region 1. 
Genomic DNA extracted from cell lines was 
processed as in Figure 22. Five independent 
clones were submitted to direct DNA sequencing 
and the obtained sequences analyzed using BiQ 
Analyzer software; results are presented as in 
Figure 22. Fourteen out of 15 CG pairs were 
analyzed for region 1 as depicted in Figure 23. The 
red lines comprise CG residues belonging to the 
LTR transposon. MDA-MB-231 cells expresses 
neither HNF1 nor B3GALT5 LTR transcript, Huh-7 
expresses HNF1 only, but not the transcript; MKN-
45 and COLO-205 cells express both, but 
transcript levels are much higher in COLO-205 
[10]. 
 
 
Conversely, a surprisingly high degree of homogeneous methylation of DNA 
region 2 was found in COLO-205 cells, which was lower in MKN-45, while in 
Huh-7 the region was largely unmethylated. Such a methylation pattern was 
destroyed by 5AZA treatment (Figure 25 A). We thus analyzed two matched 
pairs of colon specimens, and found that the methylation pattern was 
somewhat recognizable in normal mucosa, but not in cancer (Figure 25 B). 
Conversely, in two matched specimens from the pancreas, the methylation 
pattern of the same region was scarcely preserved, without differences 
between normal and cancer tissues (Figure 25 B), in accordance with the low 
levels of expression of the LTR transcript irrespective of normal or cancer 
status.  
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FIGURE 25: Lollipop representation of methylated CG residues in DNA region 2. 
Genomic DNA extracted from cell lines (A) or colon and pancreas tissues (B) was processed 
as in Figure 22. Tissue samples are those indicated in previous figures. Ten (A) or eight (B) 
independent clones were submitted to direct DNA sequencing and the obtained sequences 
analyzed using BiQ Analyzer software; results are presented as in Figure 22. Twenty-four CG 
pairs were analyzed for region 2 as depicted in Figure 23. Huh-7 cells express HNF1 but not 
B3GALT5 LTR transcript. MKN-45 and COLO-205 cells express both, but transcript levels are 
much higher in COLO-205, and drop down upon 5AZA treatment [69]. The corresponding 
levels of B3GALT5 LTR transcript in each tissue sample are presented in Figure 19. 
 
 
To confirm the potential involvement of such a region in LTR promoter 
activation, we designed ChIP experiments. Unfortunately, no commercially 
available anti-HNF1 antibodies were found suitable for ChIP assays. We tried 
specific anti-HNF1α or -HNF1β antibodies, as well as other antibodies 
recognizing both isoforms, but none worked properly. We thus tried to find 
histone modifications associated with the HNF1 binding region of the LTR 
promoter by ChIP assays with various antibodies. Using chromatin prepared 
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from COLO-205 and MKN-45 (both expressing HNF1), or MDA‐MB‐231 cells 
(not expressing HNF1), we found that H3KAc was recruited to the HNF1 
binding site and associated with LTR transcription (Figure 26 A). H3 
acetylation is indeed commonly considered as a marker of active chromatin. 
Surprisingly, H4K20 trimethylation provided a slight enrichment, while H3K4 
trimethylation did not. This was not expected, since H4K20 trimethylation and 
H3K4 trimethylation are considered markers of inactive and active chromatin, 
respectively. Interestingly, an overlapping pattern was found using PCR 
primers specific for region 2 (Figure 26 B), but not for region 3 (Figure 26 C). 
Recruitment of H3KAc to the HNF1 binding region of LTR (Figure 26 D), as 
well as to region 2 (Figure 26 E), was abolished when COLO-205 cells were 
treated with 5AZA, while it was totally lacking in Huh-7 cells (expressing 
HNF1 but lacking LTR transcription), and minimal in MDA-MB-231 cells 
expressing HNF1α (MDA-MB-231/HNF1α). Altogether, these data suggest 
that region 2 is probably involved in LTR promoter activation, which requires 
a permissive chromatin status characterized by a specific pattern of DNA 
methylation and a set of histone modifications unknown at present. 
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FIGURE 26: ChIP analysis of histone modifications of DNA regions upstream of the 
B3GALT5 LTR transcription starting site. Chromatin was prepared from different cell lines 
or clones, cross-linked, digested and immunoprecipitated with the indicated antibodies as 
reported in section 2.5. Aliquots of immunoprecipitated DNA and dilutions of non-precipitated 
(input) DNA were submitted to qPCR amplification using primer pairs specific for the HNF1 
binding region and for regions 2 and 3. The exact location of target DNA is shown in Figure 
23. The relative levels of each histone modification were calculated by a standard curve and 
normalized to the input DNA. Results are the mean ± standard deviation for at least two 
amplifications of two independent precipitations. 
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5. DISCUSSION 
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We already showed that mouse tissues, which lack CA19.9 and all type 1 
chain Lewis antigens due to the absence of α1,4 fucosyltransferase activity 
[98, 138], are stained by IH with the anti-CA19.9 antibody NS-1116-19-9. 
Conversely, reference COLO-205 and SW-1116 cells lines, as well as 
xenografts obtained with recombinant HCT-15 cells expressing B3GALT5, 
are not, indicating that the antibody loses epitope specificity and acquires 
false cross-reactivity when used in combination with histochemistry [66]. 
Here, the comparative detection of CA19.9 by IF or IH on human tissue 
sections revealed that the true antigen is scarcely detectable in colon 
mucosa and virtually absent in colon cancer. An overlapping result was 
obtained by dot-blot staining of tissue lysates where transcript analysis 
indicated low levels of B3GALT5 and ST3GAL3. These data suggest that the 
levels of B3GALT5 and ST3GAL3 transcripts do affect Lewis antigen 
patterns and amounts, as previously established for FUT3 and FUT2 [67, 
74]. In particular, low levels of B3GALT5 accompanied by low levels of 
ST3GAL3, which is reported as a frequent condition in colon cancer [79, 137, 
139], do not allow significant synthesis of CA19.9, nor elevation of circulating 
antigen per se. The origin of circulating CA19.9 antigen in colon cancer thus 
remains an open question. However, since it is restricted to patients at the 
last stage of the disease [15, 49], we speculate that it may depend on the 
concurrent involvement of the biliary system [48], since bile contains huge 
amounts of the antigen [47, 140]. In the pancreas, the expression pattern of 
type 1 chain Lewis antigens was rather different than in the colon, as was 
that of cognate glycosyltransferase transcripts. The levels of B3GALT5 
transcript were lower than in the colon, but maintained in cancer, and the 
levels of ST3GAL3 transcript were higher than in the colon. Concurrently, 
CA19.9 was present in both normal and cancer status, together with Leb and 
Lea antigens, and reactivity was always restricted to ducts or duct-like 
structures only, while the bulk of the other cancer cells were negative. The 
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relative amounts of each antigen appeared variable in different patients. In 
this regard, the FUT3 and FUT2 genotype of the patients may play a relevant 
role, as mentioned above. No qualitative differences appeared between 
normal and cancer status while dot-blot staining suggested that the amounts 
of Lewis antigens may be higher in cancer than in the normal counterpart, 
although the levels of glycosyltransferase transcripts are not. It has already 
been reported that multiple proteins carry the sLea epitope in pancreatic 
cancer but none appears responsible for cancer up-regulation [141]. Taking 
together all these observations, we speculate that Lewis antigen 
accumulation occurs as a consequence of obstructed and uncanalized 
neoformed ducts, and/or inverted polarity of transformed ductal cells [142], 
which in turn give rise to reabsorption into vessels and elevation in circulating 
levels. CA19.9 thus appears as a physiological product that acquires tumor 
marker properties, as already suggested 30 years ago [143]. According to 
our data, Leb may share the same properties in the pancreas and account 
for some of the patients where elevation of serum CA19.9 does not occur. 
Due to the relevant role of B3GALT5, we tried to elucidate the mechanism of 
differential gene regulation in the two tissues. We found that the transcription 
factors required for the activation of native and LTR promoters, NF-Y and 
HNF1, respectively, were both expressed in pancreas tissues, as expected. 
However, HNF1 is faintly detected probably because its expression is 
restricted to some cell types, namely those forming the ducts. Interestingly, 
it was faintly detected even in the pancreatic cell lines. In the analyzed 
pancreas samples, we found that the two CpG islands flanking the native 
promoter were both largely unmethylated, and remained unmethylated in 
cancer, accounting for the persistent expression of the native B3GALT5 
transcript in cancer. These findings corroborate the concept that DNA 
methylation is involved in tissue-specific gene expression [105, 114]. Based 
on the inhibitory effect of 5AZA on LTR transcription [133], we screened DNA 
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sequences upstream of the LTR promoter by bisulfite sequencing, searching 
for stretches of CG dinucleotides whose degree of methylation associates 
with LTR transcription. We found a candidate stretch of 24 CGs located about 
1000 bp upstream of the LTR promoter (region 2). They were unmethylated 
in Huh-7 cells, lacking transcription even in the presence of HNF1, and 
methylated in cells expressing the transcript. In particular, we found a kind of 
methylation motive in COLO-205 cells whose disruption by 5AZA treatment 
leads to reduced LTR transcription, as found in pancreas tissues or colon 
cancers expressing the transcript from low to undetectable levels. 
Conversely, such a methylation motive was rather preserved in colon 
mucosa expressing moderate to high levels of LTR transcript. ChIP 
experiments indicated that such a DNA sequence, referred to as region 2 
(Figure 22), is probably associated with the HNF1 binding elements of the 
LTR promoter in active chromatin, marked by histone modifications unknown 
at present. Demethylation through 5AZA treatment abolished the association 
to the HNF1 binding region, supporting the involvement of the sequence in 
transcription. Interestingly, such a region is immediately adjacent to the 
insertion of the retroviral sequence that contains the HNF1 binding site 
(Figure 22) and may play a role in stabilizing the transposon during evolution. 
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6. CONCLUSION 
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Our data suggest a novel conceptual frame underlying serum CA19.9 and 
type 1 chain antigen elevation in gastrointestinal cancers, where 
obstruction/reverse of polarity and individual glycosyltransferase pattern play 
the pivotal role in a tissue-specific manner. In pancreatic cancer, Lea and 
Leb appear candidate alternative markers for some CA19.9-negative 
patients. In colon cancer, the more probable origin is from outside the organ, 
and bile is the likely candidate. In gastric and bile duct cancers, information 
is lacking. In all cases, we suggest that for a rational clinical use and for 
research, the simple serum CA19.9 determination is not sufficient, and is 
potentially misleading. More experimental work is necessary, studying each 
patient from a personalized perspective. Multiple antigens should be 
detected in the available surgery specimens by proper techniques (no 
immunohistochemistry with NS- 1116-19-9 antibody), and in the blood of the 
same patients. FUT3 and FUT2 allelic status relative to common mutations 
should be determined, together with the levels of B3GALT5 and ST3GAL3 
transcripts. Antigen determination in a bile sample when available would be 
very useful. These aspects can be studied using commonly available 
procedures in vast cohorts of patients, while the role and mechanisms of 
reverse of polarity in secretive cancer cells deserves more attention and 
requires elucidation at the molecular level. Although surprising after 30 years 
since their first use, it seems that the story of CA19.9 and related antigens 
has to be rewritten and promises fruitful clinical applications. 
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